EP2109602A2 — Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
Assigned to Paratek Pharmaceuticals Inc · Expires 2009-10-21 · 17y expired
What this patent protects
The present invention pertains, at least in part, to a substituted tetracycline compound of Formula (I): wherein X is CHC(R13VY), CR6 R6, C=CR6 R6, S, NR6, or O; E is NR7dR7β, OR7f or (CH2)o.iC(=W)WR7s; W is O, S, NR711 or CR75R7*; W is O, S or NR7*; These tetracycline compounds …
USPTO Abstract
The present invention pertains, at least in part, to a substituted tetracycline compound of Formula (I): wherein X is CHC(R13VY), CR6 R6, C=CR6 R6, S, NR6, or O; E is NR7dR7β, OR7f or (CH2)o.iC(=W)WR7s; W is O, S, NR711 or CR75R7*; W is O, S or NR7*; These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.